IMPACT member Jason Karlawish, MD, weighs in on a proposed Alzheimer’s diagnosis tool – a simple blood test. An independent Alzheimer’s working group is finalizing its recommendations for diagnosing Alzheimer’s based on the presence of amyloids in a blood test alone, independent of symptoms. Karlawish voices concern that the amyloid blood test is not yet ready for clinical practice.
Building the nation’s capacity to conduct pragmatic clinical trials embedded within healthcare systems for people living with dementia and their care partners